Herpes zoster (HZ), also commonly known as shingles, is characterized by a bandlike rash in the dermatome that corresponds to the affected nerve. Pain is prevalent in HZ patients, which may be provoked by light touch. Postherpetic neuralgia (PHN) is one of the most common complications of HZ and it is generally intractable to treat. At present, common treatment methods for HZ include anti-inflammatory, antiviral, analgesic, and neuroleptic regimens. Nevertheless, the application of these therapies can sometimes be limited by side effects. In this scenario, it is urgent to seek alternative non-pharmacological therapies for treating HZ. Intradermal acupuncture (IDA) is a common type of acupuncture. By retaining the needles for a much longer duration than other common modalities of acupuncture, IDA can prolong the sustained effect of acupuncture. In addition, characterized by mild pain during the insertion of intradermal needles, IDA is more suitable for patients who fear conventional acupuncture and it is also easy to operate by practitioners. Therefore, concerning the treatment of pain conditions, such as acute HZ, it may have certain advantages over conventional acupuncture. Thus, The aim of this trial is to evaluate the efficacy and safety of IDA for acute HZ.
This randomized controlled trial will enroll 72 eligible patients with acute herpes zoster. Participants who are confirmed eligibility will be randomly allocated to either the IDA group or the sham IDA group in a 1:1 ratio. The duration of the trial will include two study phases, including a 1-month intervention phase and a 3-month follow-up phase.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
72
In addition to basis standard pharmacological treatments, intradermal needles will be inserted in each selected acupoint and retained in place for 48 hours. Points around the herpes zoster sites (about 1 cm peripherally) are selected for intradermal acupuncture (IDA) encircled needling. Meanwhile, intradermal acupuncture is also performed in Ashi acupoints in the distribution area of herpes zoster. The operator will tear off the adhesive tape of intradermal needles and stick them on the selected acupoints, and then apply pressure on intradermal needles over the selected acupoints perpendicularly according to the patient's tolerance. In addition, patients will be instructed to press the intradermal needles 4 times per 24 hours throughout the needle retention period, with the aim to increase stimulation for treatment enhancement, each time lasting around 30 seconds.
In addition to basis standard pharmacological treatments, sham intradermal acupuncture will be implemented in the same acupoints as the intradermal acupuncture group using pseudo-intradermal needling. Additionally, participants in the sham intradermal acupuncture group will be treated in another room to avoid direct communications with subjects in the IDA group.
the Third Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
NOT_YET_RECRUITINGThe Third Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
RECRUITINGChange in pain intensity
The pain intensity is assessed using the 10-point Visual Analog Scale (VAS)
Time frame: at baseline (pre-treatment), at 1 month after intervention, at 3-month follow-up
Stopping time of herpes zoster
the number of days required for herpes zoster to stop increasing
Time frame: through study completion (up to 4 months)
Crusting time of herpes zoster
the number of days required for herpes zoster crusting
Time frame: through study completion (up to 4 months)
Removal time of herpes zoster scabs
the number of days required for all herpes zoster scabs to be completely shed
Time frame: through study completion (up to 4 months)
Change in the temperature of regions of interest (ROIs)
The temperature of ROIs will be assessed by infrared thermography.
Time frame: at baseline (pre-treatment), at 1 month after intervention, at 3-month follow-up
Incidence rate of postherpetic neuralgia (PHN)
The incidence rate of PHN will be assessed by calculating the percentage of patients who suffer from PHN
Time frame: at 3-month follow-up
Change in quality of life
The 36-item Short Form Health Survey (SF-36) will be utilized to assess the quality of life.
Time frame: at baseline (pre-treatment), at 1 month after intervention, at 3-month follow-up
Adverse events
Incidence of adverse events
Time frame: through study completion (up to 4 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.